In patients with metastatic melanoma, the combination of bevacizumab with the anti-CTLA-4 monoclonal antibody ipilimumab reverses tumor-associated EC anergy increasing the expression of the adhesion molecules E-selectin, ICAM1, and VCAM1 which enhances the recruitment of T cells in the tumor bed and improves the clinical outcome (257). Here, CTLA4 is linked to neoplasm.